{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-066575","form_type":"8-K","ticker":"APGE","cik":"0001974640","company_name":"Apogee Therapeutics, Inc.","filed_at":"2026-05-27T10:40:32+00:00","discovered_at":"2026-05-27T10:45:01.346592+00:00","generated_at":"2026-05-27T10:45:17.600815+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apogee secures up to $1.3B non-dilutive financing from Blackstone for zumilokibart","bullets":["$100M upfront received; additional $100M upon Phase 3 enrollment, $200M on positive Phase 3 data.","Up to $400M more at FDA approval ($150M at Apogee's option); total synthetic royalty up to $800M.","Low-to-mid single digit tiered royalties for 15 years on worldwide net sales; no royalties above $8B.","Up to $500M senior corporate debt available at mutual consent with Blackstone.","Company removes cash runway guidance; combined with $1.3B current cash positions for self-sustainability."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-066575","json":"https://secwatch.observer/filing/0001104659-26-066575.json","markdown":"https://secwatch.observer/filing/0001104659-26-066575.md","text":"https://secwatch.observer/filing/0001104659-26-066575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926066575/0001104659-26-066575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1974640/000110465926066575/tm2615568d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T10:45:17.600815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001213900-26-063161","ticker":"OPTU","company_name":"Optimum Communications, Inc.","filed_at":"2026-06-01T12:16:33+00:00","headline":"Optimum raises $500M via preferred units, starts $300M tender at $2.50 to shield assets from CSC debt","event_type":"other_material","sec_items":["1.01","3.02","7.01","8.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063161","json":"https://secwatch.observer/filing/0001213900-26-063161.json","markdown":"https://secwatch.observer/filing/0001213900-26-063161.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/0001213900-26-063161-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1702780/000121390026063161/ea0292871-8k_optimum.htm"},"side_by_side_evidence":null},{"accession":"0002007587-26-000071","ticker":"AII","company_name":"American Integrity Insurance Group, Inc.","filed_at":"2026-06-01T20:31:10+00:00","headline":"American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0002007587-26-000071","json":"https://secwatch.observer/filing/0002007587-26-000071.json","markdown":"https://secwatch.observer/filing/0002007587-26-000071.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/0002007587-26-000071-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2007587/000200758726000071/aii-20260601.htm"},"side_by_side_evidence":null},{"accession":"0000798359-26-000057","ticker":"CSR","company_name":"CENTERSPACE","filed_at":"2026-06-01T20:30:13+00:00","headline":"Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000798359-26-000057","json":"https://secwatch.observer/filing/0000798359-26-000057.json","markdown":"https://secwatch.observer/filing/0000798359-26-000057.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/0000798359-26-000057-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/798359/000079835926000057/iret-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":null},{"accession":"0001570585-26-000084","ticker":"LBTYA","company_name":"Liberty Global Ltd.","filed_at":"2026-06-01T20:07:09+00:00","headline":"Liberty Global names Stephen van Rooyen as Ziggo Group CEO; plans Amsterdam listing in 2027","event_type":"other_material","sec_items":["7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001570585-26-000084","json":"https://secwatch.observer/filing/0001570585-26-000084.json","markdown":"https://secwatch.observer/filing/0001570585-26-000084.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570585/000157058526000084/0001570585-26-000084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570585/000157058526000084/lbtya-20260601.htm"},"side_by_side_evidence":null},{"accession":"0001193125-26-251399","ticker":"IDYA","company_name":"IDEAYA Biosciences, Inc.","filed_at":"2026-06-01T20:05:32+00:00","headline":"IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma","event_type":"other_material","sec_items":["7.01","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251399","json":"https://secwatch.observer/filing/0001193125-26-251399.json","markdown":"https://secwatch.observer/filing/0001193125-26-251399.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/0001193125-26-251399-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1676725/000119312526251399/d138848d8k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-063486","ticker":"MDAI","company_name":"Spectral AI, Inc.","filed_at":"2026-06-01T20:01:42+00:00","headline":"Spectral AI gets FDA clearance for DeepView burn indication; targets first commercial sales by year-end 2026","event_type":"other_material","sec_items":["5.07","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063486","json":"https://secwatch.observer/filing/0001213900-26-063486.json","markdown":"https://secwatch.observer/filing/0001213900-26-063486.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/0001213900-26-063486-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026063486/ea0292962-8k_spectral.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-026544","ticker":"LIXT","company_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC.","filed_at":"2026-06-01T12:55:34+00:00","headline":"Lixte Biotechnology pivots to AI energy infrastructure; appoints Denham Capital founder to board","event_type":"other_material","sec_items":["5.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026544","json":"https://secwatch.observer/filing/0001493152-26-026544.json","markdown":"https://secwatch.observer/filing/0001493152-26-026544.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/0001493152-26-026544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1335105/000149315226026544/form8-k.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}